Yu go mɔs dɔn yɛri bɔt di ɔmon we dɛn kɔl insulin. Dis nem kin kam bɔku, mɔ we wi de tɔk bɔt dayabitis. Bɔt yu dɔn ɛva yɛri bɔt di ɔmon we tan lɛk insulin-layk growth factor-1, ɔ IGF-1 fɔ shɔt tɛm? Na ɔmon we gɛt fɔ du wit insulin bak, ɛn i de wok jɔs lɛk insulin. Tide, lɛ wi tɔk bɔt wetin na IGF-1 ɛn aw i gɛt fɔ du wit dayabitis.
Fɔ tɔk am simpul wan, wetin na IGF-1?
`insulin-like Growth Factor-1` כ `IGF-1` na wan rili imכtant כmon we wi liva de mek. wan pan di men wok dεm we i de du na fכ signal wi bon dεm εn mכsul dεm fכ "grכw fayn fayn wan." Dat min se i rili impɔtant fɔ mek wi bɔdi gro.
Dis ɔmon rili fiba insulin. I kin afɛkt bak di we aw wi sɛl dɛn de yuz di shuga ɔ glukɔs we de na wi blɔd. So naw yu kin si se big kɔnekshɔn de bitwin dɛn tu.
Di rilayshɔn wit Tayp 2 Dayabitis
Fɔs, lɛ wi mɛmba aw dayabitis kin kam. di כmon insulin de εp di glukכs we wi de gεt frכm di it we wi de it fכ go insay wi sεl dεm εn mek εnεji. Tink bɔt am lɛk se insulin tan lɛk ki, sɛl tan lɛk rum, ɛn di domɔt na di sɛl na di lɔk. So, we dεn put dis ki (insulin) εn opin di lכk, glukכs kin go insay di sεl.
Bɔt sɔntɛnde wi bɔdi nɔ kin ansa dis insulin fayn fayn wan. Wi kin kɔl am insulin rɛsistɛns . I tan lɛk lɔk we dɔn rɔsti we di ki nɔ go ebul fɔ tɔn. Dɔn wi pankrias kin tray fɔ mek mɔ insulin fɔ du di wok. Bɔt sɔntɛnde, i nɔ kin ebul fɔ du am bak. di rizulεt na dat glukכs nכ kin ebul fכ go insay di sεl dεm εn i de bכku insay di bכdi. Dɔn, dis sik kin bi Tayp 2 Dayabitis .
Naw na dis say `IGF-1` de kam in. Risach dɔn sho se pipul dɛm we gɛt smɔl `IGF-1` lɛvɛl de pan ay risk fɔ gɛt wan klasta ɔf kɔndishɔn dɛm we dɛn kɔl `Mɛtabolik Sindrom`.
Metabolic Syndrome nɔto wan sik. Na wan kɔmbaynshɔn fɔ sɔm wɛlbɔdi prɔblɛm dɛn lɛk ay blɔd prɛshɔn, ay kɔlɔstrel, ɛn bɛlɛ fat. We ɔl dɛn tin ya kam togɛda, di risk fɔ gɛt at sik ɛn dayabitis kin bɔku pasmak.
Dis min se if yu IGF-1 lɛvɛl smɔl, yu go gɛt ɔda prɔblɛm dɛn we kin mek yu gɛt dayabitis.
So IGF-1 kin trit dayabitis?
Dis na di kwɛstyɔn we di wan dɛn we de du risach de tray fɔ ansa dɛn tɛm ya. wan klyu fכ dis na wan dכg we dεn kכl `mecasermin (Increlex).` Dis na sεntetik, dat na, `IGF-1` כmon we dεn mek na lab. Dɔktɔ dɛn kin yuz dis mɛrɛsin fɔ trit yɔŋ pikin dɛn we nɔ de gro fayn.
Bɔt wan pan di sayd ɛfɛkt dɛm fɔ dis drɔg na we di blɔd shuga lɛvɛl de go dɔŋ, dat na we wan sik we dɛn kɔl `Hypoglycemia` kin apin. Dis bin mek di wan dɛn we de du risach pe atɛnshɔn to am. Insay leta stɔdi, we dɛn gi big pipul dɛn we gɛt tayp 2 dayabitis dis `IGF-1`, dɛn si bak se dɛn blɔd shuga lɛvɛl dɔn go dɔŋ. Apat frɔm dat, dɛn insulin rɛsistɛns bin impɔtant bad bad wan.
Bɔt... dis stil de na di risach stej. Bikɔs IGF-1 na ɔmon we de du bɔku tin na di bɔdi, bɔku tin stil de fɔ lan bɔt aw i de wok. na dis tεm, dεn כnli apruv IGF-1 fכ gכt prכblεm dεm na pikin dεm. Dɛn nɔ dɔn gri fɔ am yet as tritmɛnt fɔ dayabitis.
Lɛ wi no bak bɔt di bad bad tin dɛn we kin apin to wi.
`IGF-1` no bi somtin fo ple wit. I kin mek pɔsin gɛt siriɔs sayd ɛfɛkt. I rili impɔtant fɔ no bɔt dis.
| Sayd ɛfɛkt we pɔsin kin gɛt | Simpul ɛksplen |
|---|---|
| Swel na di Retina | di rεtina na di layt we de insay di yay we de sεnd wetin wi de si to di bren. Dis swel kin mek yu si bad bad wan. |
| Siriɔs pen na di mɔsul ɛn jɔyn dɛn | Sɔntɛm pen kin de na di mɔsul ɛn jɔyn dɛn na di bɔdi we yu nɔ go ebul fɔ bia. |
| Bɛl in Palsi | Dis na we wan say na di fes wik wantɛm wantɛm ɛn drɔp dɔŋ, ɛn i kin tan lɛk se pɔsin dɔn strok. |
| Risk fɔ gɛt kansa | (I rili impɔtant) Dɛn dɔn si se IGF-1 gɛt fɔ du wit di divɛlɔpmɛnt fɔ di kansa na di bɔdi, di kɔlon, di lɔng, ɛn di prɔstat. |
Di tru tin bɔt supamakit
Dis na tɔpik we impɔtant to bɔku pipul dɛn. Sɔm bɔdi bilda ɛn atlet dɛn kin yuz IGF-1 sɔpɔtmɛnt, ilɛksɛf na ɔva-di-kɔnta ɔ prɛskrishɔn, fɔ mek dɛn bɔdi bɔku ɛn fɔ mek dɛn gɛt mɔ trɛnk.
Bɔt mɛmba se di Wɔl Anti-Doping Ajɛns (WADA) dɔn ban ɔl kayn ɔmon we dɛn kɔl IGF-1, ivin di wan dɛn we dɛn kin yuz fɔ sɔpɔt di ɔmon.
WADA se ivin di `IGF-1` we dɔktɔ gi yu kin mek yu jɔyn, liva, ɛn at pwɛl fɔ ɔltɛm if yu nɔ yuz am di rayt we. So wetin bɔt supamakit dɛn we dɛn de sɛl we nɔ gɛt ɛni lɔ? Nɔn pan wi nɔ no wetin rili de insay dɛn.
Ɔda pipul dɛn kin yuz dɛn fɔ anti-aging ɔ fɔ jenɛral wɛlbɔdi bɛnifit. Na tru se as wi de ol, wi bɔdi nɔ de mek IGF-1 smɔl. Bɔt no sayɛns pruf nɔ de fɔ se if yu tek IGF-1 sɔpɔtmɛnt dɛn, dat go ɛp yu fɔ de yɔŋ.
Dis aidia kɔmɔt frɔm risach pan di dayabitis drɔg we dɛn kɔl metformin. Insay dɛn stɔdi dɛn de, wom ɛn mays dɛn bin liv lɔng we dɛn gi dɛn mɛtfɔmin. Bɔt dɛn nɔ no yet aw i go afɛkt mɔtalman.
So, if yu de tink fɔ tek `IGF-1` suplimɛnt, duya nɔ ivin tink bɔt am. Mek shɔ se yu tɔk to yu dɔktɔ bifo yu du dat. If yu injekt dɛn kayn pawaful tin dɛn de na yu bɔdi we yu nɔ gɛt dɔktɔ advays, dat kin mek yu fil bad we yu nɔ go ebul fɔ imajin.
Mɛsej we dɛn kin kɛr go na os
- `IGF-1` na nεchכral כmon we sכm kayn insulin we implεnt fכ wi bכdi fכ gro.
- di lכw lεvεl dεm fכ IGF-1 na di bכdi de lεk wit di kכndyushכn we dεn kכl Mεtabolik Sεndrכm, we de mek di risk fכ gεt dayabitis εn at sik dεm.
- Pan ɔl we dɛn dɔn du risach bɔt aw fɔ yuz IGF-1 as tritmɛnt fɔ dayabitis, nɔto tritmɛnt we dɛn dɔn gri fɔ yuz yet.
- Dis ɔmon kin mek yu gɛt siriɔs sayd ɛfɛkt lɛk we yu nɔ de si fayn, yu jɔyn dɛn kin pen, ɛn yu kin gɛt kansa.
- Di yus fɔ `IGF-1` suplimɛnt na di makit rili denja. Dɛn de bak na di list we di World Anti-Doping Agency gɛt.
- Ɔltɛm, go to yu dɔktɔ bifo yu yuz ɛni sɔpɔt ɔ mɛrɛsin.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt